Revenue
No reported data
Estrella Immunopharma, Inc. (ESLA)
Price—Loading quote
Net income
2021
2022
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2024
2024
2025
Financial statements
| 2025 | 2024 | 2022 | 2021 | |
|---|---|---|---|---|
| Research & development | $10.2M | $4.1M | — | — |
| Operating expenses | $13.1M | $7.3M | $1.4M | $178,992 |
| Operating income | −$13.1M | −$7.3M | −$1.6M | −$249,146 |
| Net income | −$13.1M | −$7.3M | −$996,104 | −$247,718 |
| Basic EPSper diluted share | -$0.35 | -$0.27 | — | — |
| Diluted EPSper diluted share | -$0.35 | -$0.27 | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Oct 7, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share | 1.0K | $1.33 | $1.3K | 265.5K |
| Sep 22, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share · indirect | 1.0K | $1.16 | $1.2K | 16.7K |
| Sep 11, 2025Form 4 | Xu JiandongChief Financial Officer | BuyCommon Stock, par value $0.0001 per share | 100 | $1.04 | $104.00 | 264.6K |